Overland Pharmaceuticals

Overland Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for underserved patients in Asia and worldwide. Co-founded by Hua Mu, MD, PhD, and Ed Zhang, MBA, the company operates from offices in Shanghai, Beijing, and Boston. With a team of 20 to 49 employees, Overland generates approximately $11 million in revenue.

The company focuses on oncology treatments, including antibody-drug conjugates (ADCs), allogeneic cell therapies, and RNAi therapeutics. Its drug pipeline features candidates at various development stages, such as Loncastuximab tesirine for lymphoma and Mipasetamab Uzoptirine for solid tumors. Overland also collaborates with partners, including a joint venture with ADC Therapeutics, to enhance the development and commercialization of its therapies.